Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection

Summary

Treatment of acute primary HIV infection may improve long-term outcome. However, optimal treatment is still debated. The ANRS 112-INTERPRIM trial evaluates three different therapeutical strategies, combining permanent or intermittent HAART and a cytokine, interferon alpha, in order to determine which combination allows the best control of HIV viremia after 24 weeks of antiretroviral treatment interruption

Timeline

Start

2002-05

Primary completion

—

Completion

2006-03

Drugs

Indications